Paclitaxel nanoparticle - Dabur Pharma

Drug Profile

Paclitaxel nanoparticle - Dabur Pharma

Alternative Names: Nanoxel; PNP

Latest Information Update: 29 May 2008

Price : $50

At a glance

  • Originator Dabur Pharma
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Apr 2008 Dabur Pharma has been acquired by Fresenius Kabi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top